- Trial phase
- Phase 2
- Time to market
- At least 4-6 years away. The drug is in Phase 2; a large Phase 2b study began in July 2026 with an estimated completion date of October 2031. Phase 3 trials and regulatory review would follow.
- Why 3/10
- ABBV-466 is a Phase 2-stage asset at a large-cap diversified pharma. The next hard catalyst would be a topline readout from the Phase 2b platform study (M26-266), which began enrolling in July 2026 with no announced readout date. With no dated binary catalyst within ~12 months and the drug representing a tiny fraction of AbbVie's enterprise value, the impact score is low.
The next catalyst for ABBV-466 is further data readouts from the ongoing Phase 2b platform study (M26-266 / NCT07697456), which began enrolling ~2,000 patients in July 2026 across Crohn's disease and ulcerative colitis. No specific topline readout date has been announced. Given AbbVie's diversified pipeline and market cap, ABBV-466 data alone is unlikely to drive a major share-price move in either direction in the near term.
Price Chart
Executive Summary
ABBV-466 is AbbVie's investigational fixed-dose combination of its blockbuster IL-23 inhibitor Skyrizi (risankizumab) and an anti-alpha-4 beta-7 integrin antibody called trosunilimab, designed for Crohn's disease and ulcerative colitis. On October 19, 2026, AbbVie reported Phase 2a TARGET-CD data showing the combination achieved 30.2% endoscopic remission at Week 12 (primary endpoint) and 40.5% at Week 24, roughly double the rates of either monotherapy, with comparable safety. A larger Phase 2b platform study (M26-266) began enrolling ~2,000 patients in July 2026. For a non-medical investor, ABBV-466 is an early-stage pipeline asset at a $295 billion mega-cap pharma; the data are encouraging but years from potential approval, and the drug represents a tiny fraction of AbbVie's valuation.
How It Works
ABBV-466 is a fixed-dose combination of two antibody drugs. The first, risankizumab (marketed as Skyrizi), blocks IL-23, a protein that drives inflammation in the gut. The second, trosunilimab, blocks alpha-4 beta-7 integrin, a molecule that helps inflammatory immune cells travel to the intestine. By hitting both targets at once, the combination aims to shut down gut inflammation through two separate pathways.
Trial Status
Phase 2a TARGET-CD study (NCT06548542) completed enrollment of 300 patients and reported positive topline data in October 2026. A larger Phase 2b platform study (M26-266 / NCT07697456) began enrolling approximately 2,000 patients in July 2026, evaluating ABBV-466 in both Crohn's disease and ulcerative colitis.
The Two-Sided Case
Upcoming Catalysts
- Further data readouts from the ongoing Phase 2b platform study M26-266 (no specific date announced)
- Potential expansion into ulcerative colitis based on the Phase 2b platform design
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report